Literature DB >> 34124700

SARS-CoV-2 RNA detection in cerebrospinal fluid: Presentation of two cases and review of literature.

María Belén Luis1, Nora Fernández Liguori1, Pablo Adrián López2, Ricardo Alonso1.   

Abstract

Neurological manifestations of SARS-CoV-2 infection are multiple and heterogeneous. However, confirmation of nervous system impairment by viral RNA detection in cerebrospinal fluid (CSF) is uncommon. We report two cases of central nervous system (CNS) involvement with positive real-time reverse-transcriptase polymerase chain reaction (RT-PCR) test in CSF.
© 2021 The Authors.

Entities:  

Keywords:  Encephalitis; Meningoencephalitis; Myelitis; Neuroimaging; SARS-CoV-2; SARS-CoV-2 RNA; SARS-CoV-2 infection; SARS-CoV-2 neurological manifestations

Year:  2021        PMID: 34124700      PMCID: PMC8184365          DOI: 10.1016/j.bbih.2021.100282

Source DB:  PubMed          Journal:  Brain Behav Immun Health        ISSN: 2666-3546


Introduction

Since the beginning of the ongoing SARS-CoV-2 pandemic, several studies describing the neurological manifestations of the disease have been published. Although this virus has special predilection for the respiratory and cardiovascular systems, its potential neurotropism is also known (Ahmad and Rathore, 2020). The most common neurological manifestations are smell and taste disturbances, headache, myalgia, dizziness and impaired consciousness. Other reported clinical pictures include ataxia, neuropathies, meningoencephalitis, demyelinating disorders and cerebrovascular disease (Favas et al., 2020; Ibrahim, 2020). As described in previous reports, patients with severe forms of the disease are more prone to developing CNS impairment than those with mild to moderate infections (Mao et al., 2020; Helms et al., 2020). The exact explanation for SARS-CoV-2 CNS involvement is not well established yet, but two possible mechanisms have been proposed: direct viral CNS invasion or cytokine cascade induced by the virus (Tandon et al., 2021; Al-olama et al., 2020). Despite the wide variety of published literature about neurological disorders associated with SARS-CoV-2 infection, there are few reported cases with viral RNA detection in CSF. We present two cases of young patients with CNS disease due to SARS-CoV-2, with positive viral RT-PCR test in CSF.

Case 1

A 25-year-old female was referred to our hospital due to acute impairment of consciousness. She had a personal history of anxiety disorder and had been diagnosed with mild COVID-19 (odynophagia and hyposmia) four months before admission with complete recovery of symptoms afterwards. Ten days before hospitalization the patient began with a holocranial headache, vomits and fever, and one week later she had a tonic-clonic seizure. At initial evaluation in another hospital, neck stiffness was noted. Brain computed tomography (CT) scan was unremarkable and there were no positive findings in blood tests. Analysis of CSF yielded hypoglycorrhachia (37 ​mg/dl), hyperproteinorrachia (247 ​mg/dl) and no cells. Acute bacterial meningitis was suspected and treatment with Ceftriaxone was started. The patient quickly developed an altered mental state, and antimicrobial therapy was switched to Meropenem, Vancomycin and Acyclovir. She was then transferred to our hospital. At the initial neurological examination, mutism and stupor were observed. The pupils were symmetrical and reactive to light. There were no signs of cranial nerve involvement. She had nuchal rigidity and upper limbs hypertonia. Shortly after admission she developed a comatose state and a non-convulsive status epilepticus was ruled out by EEG. The new CSF examination revealed normal opening pressure, lymphocytic pleocytosis (380/mm3 – 90% lymphocytes), hyperproteinorrachia (98.3 ​mg/dl), normal glucose level (57 ​mg/dl) and increased lactate concentration (4.32 ​mmol/l). Brain and spinal cord magnetic resonance imaging (MRI) were abnormal (Fig. 1, Fig. 2). Extensive work-up was conducted to exclude secondary causes such as infection, autoimmune, metabolic and endocrinological diseases (Table 1). The RT-PCR test for SARS-CoV-2 was performed on samples from nasopharyngeal swab and CSF. The specific SARS-CoV-2 RNA was detected in CSF whereas the nasopharyngeal swab test was negative.
Fig. 1

Case 1 Brain Mri Findings

(A - B) Hyperintense lesions on fluid-attenuated inversion-recovery (FLAIR) sequence involving the cerebellum, thalamus and basal ganglia. (C–D) Focal area of markedly increased signal on diffusion-weighted imaging (DWI) with decrease apparent diffusion coefficient (ADC) in the splenium of the corpus callosum.

Fig. 2

Case 1 Spinal Cord Mri Findings

(A-D) Signal hyperintensity on Short Tau Inversion Recovery (STIR) sequence extending from C2 to Th3 level and from Th5 to Th10 (longitudinally extensive myelitis), with patchy and eccentric contrast enhancement. T1 post contrast cervical and lumbar pial enhancement associated to conus medullaris enhancement.

Table 1

Case 1 and 2 csf analysis and blood tests.

CSFCASE 1
CASE 2
First hospitalSecond hospital
White blood cell count/mm30380 – 90% mononuclear0
Proteins (mg/dl)24798.395.9
Glucose (mg/dl)375743
Lactic acid (mmol/L)Not available4.322.21
Culture (bacterial, fungal and KOCH)NegativeNegativeNegative
Viral PCR (Herpes simplex I/II, Human herpes virus VI, Varicella Zoster, Cytomegalovirus, Epstein Barr, Enterovirus, Coxsackie)Not availableNegativeAdenovirus PCR: NegativeNegative
Mycobacterium tuberculosis PCRNot availableNegativeNot available
Neuronal autoantibodies (Anti-NMDAR, AMPAR, CASPR2, LGI1, GABAbR)Not availableNegativeNot available
Blood tests
Neuronal autoantibodies: - Anti-NMDAR, AMPAR, CASPR2, LGI1, GABAbR - Anti-GAD - Anti-Hu, Ri, YoNot availableNegativeNot available
 AQP4-IgGNot availableNegativeNot available
 MOG-IgGNot availableNegativeNot available
ANA, Anti- dsDNA, RF, RA latex turbid test, LAC, ACL, anti-CCP,Complement C3/C4Not availableNegativeNot available
 TSHNot availableNegativeNegative
 HIVNot availableNegativeNegative
 VDRLNot availableNegativeNegative
Hepatitis B/CNot availableNegativeNegative
Cytomegalovirus, Epstein Barr, Mycoplasma and Dengue IgMNot availableNegativeNot available
Vitamin B12, folic acidNot availableNormalNot available

NMDAR: N-methyl-d-aspartate receptor; AMPAR: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; CASPR2: contactin-associated protein–like 2 receptor; LGI1: leucine-rich glioma-inactivated 1; GABABR: γ-aminobutyric acid type B receptor; GAD: Glutamic acid decarboxylase; AQP4-IgG: Aquaporin-4 antibodies; MOG-IgG: Myelin oligodendrocyte glycoprotein antibodies; ANA: Anti-nuclear antibody; Anti-dsDNA: Anti double-stranded DNA; RF: Rheumatoid Factor; RA latex turbid test: Rheumatoid arthritis latex turbid test; LAC: Lupus anticoagulant; ACL: Anticardiolipin antibodies; Anti-CCP: Anti-cyclic citrullinated peptide antibodies; TSH: Thyroid-stimulating hormone; VDRL: Venereal Disease Research Laboratory.

Case 1 Brain Mri Findings (A - B) Hyperintense lesions on fluid-attenuated inversion-recovery (FLAIR) sequence involving the cerebellum, thalamus and basal ganglia. (C–D) Focal area of markedly increased signal on diffusion-weighted imaging (DWI) with decrease apparent diffusion coefficient (ADC) in the splenium of the corpus callosum. Case 1 Spinal Cord Mri Findings (A-D) Signal hyperintensity on Short Tau Inversion Recovery (STIR) sequence extending from C2 to Th3 level and from Th5 to Th10 (longitudinally extensive myelitis), with patchy and eccentric contrast enhancement. T1 post contrast cervical and lumbar pial enhancement associated to conus medullaris enhancement. Case 1 and 2 csf analysis and blood tests. NMDAR: N-methyl-d-aspartate receptor; AMPAR: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; CASPR2: contactin-associated protein–like 2 receptor; LGI1: leucine-rich glioma-inactivated 1; GABABR: γ-aminobutyric acid type B receptor; GAD: Glutamic acid decarboxylase; AQP4-IgG: Aquaporin-4 antibodies; MOG-IgG: Myelin oligodendrocyte glycoprotein antibodies; ANA: Anti-nuclear antibody; Anti-dsDNA: Anti double-stranded DNA; RF: Rheumatoid Factor; RA latex turbid test: Rheumatoid arthritis latex turbid test; LAC: Lupus anticoagulant; ACL: Anticardiolipin antibodies; Anti-CCP: Anti-cyclic citrullinated peptide antibodies; TSH: Thyroid-stimulating hormone; VDRL: Venereal Disease Research Laboratory. After one week in intensive care unit (ICU) with mechanical ventilation, the physical examination revealed bradylalia, square wave jerks, ataxia, myoclonus in four limbs and urinary retention. The patient developed subsequently significant clinical recovery, remaining only with mild gait disturbance. She was finally discharged after three weeks of hospitalization.

CASE 2

A 41-year-old male, with a history alcoholism, iron deficiency anemia and chronic cardiovascular disease, was hospitalized because of a septic shock secondary to a skin and soft tissue infection. He had a favorable clinical course and completed antibiotic therapy. As part of our institutional protocol, he was performed a nasopharyngeal swab RT-PCR test for SARS-CoV-2 that resulted positive. The chest computed tomography scan was normal and the patient remained asymptomatic. After 20 days, he developed disorientation, psychomotor agitation and rapidly reached a stuporous state. The rest of the neurological examination was unremarkable. Blood test yielded only a mild chronic hyponatremia. Brain MRI exhibited no pathological features. A lumbar puncture was performed and the CSF showed mildly increased protein level (95.9 ​mg/dl), normal glycorrhachia (43 ​mg/dl) and no cells. RT-PCR SARS-CoV2 test was positive in CSF. Further work-up excluded other infectious etiologies. On the following days, he experienced spontaneous complete recovery.

Discussion

Approximately one third of SARS-CoV-2 infected patients develop neurological manifestations that involve predominantly the CNS (Ibrahim, 2020; Mao et al., 2020). We report two cases of CNS manifestations of SARS-CoV-2 infection, confirmed by the detection of viral RNA in CSF. The first case is a female patient who presented with meningoencephalitis and myelitis four months after a mild SARS-CoV-2 infection. The second one is a patient with a SARS-CoV-2 infection entirely confined to the CNS (encephalitis), with no involvement of other organ systems. Several hypotheses have been proposed in order to explain this neurological involvement. One explanation is CNS penetration through hematogenous spread via permeable blood-brain barrier, or retrograde neuronal route through the cribriform plate and olfactory bulb (Tandon et al., 2021; Wu et al., 2020; Montalvan et al., 2020). The ability of SARS-CoV-2 spike protein to bind to angiotensin-converting enzyme 2 (ACE-2) receptors on the capillary endothelium may be responsible for facilitating viral entry into the CNS (Al-olama et al., 2020; Wu et al., 2020). Another hypothesis is based on the inflammatory cytokine release leading to a cascade of immune cells within the CNS. In the latter, the consequent endothelial dysfunction predisposes to thrombosis or hemorrhage and results in stroke (Tandon et al., 2021; Al-olama et al., 2020). Furthermore, it is believed that para- and post-infectious complications due to dysregulation of the immune system may lead to antibody mediated damage of the nervous system, causing encephalitis, Guillain Barre Syndrome and its variants (Guilmot et al., 2021; Franke et al., 2021). Autopsy performed in patients with SARS-CoV-2 infection showed hyperemic and edematous brain tissue and neuronal degeneration (National Health Commision & State Administration of Traditional Chinese Medicine, 2020). As in our cases, it has been previously described that a positive nasal swab does not correlate with the presence or absence of the virus in the CSF of patients with neurological symptoms (Tandon et al., 2021). To date, only a small proportion of reported patients with neurological manifestations and CSF analysis, had positive RT-PCR in CSF (Helms et al., 2020; Moriguchi et al., 2020; Virhammar et al., 2020; Khodamoradi et al., 2020; Barros Domingues et al., 2020; Fadakar et al., 2020; Duong et al., 2020; Huang et al., 2020; Westhoff et al., 2020; Mardani et al., 2020; Cebrián et al., 2020; Novi et al., 2020). Clinical and paraclinical findings of these patients are summarized in Table 2. The most frequent CSF findings were occasionally hyperproteinorrachia and mild lymphocytic pleocytosis. Helms et al. reported a cohort of 118 ICU patients with acute respiratory distress syndrome due to SARS-CoV-2 infection who developed delirium and/or abnormal neurological examination. CSF analysis was performed in 25 of those patients, with positive RT-PCR SARS-CoV-2 in only one patient (Helms et al., 2020).
Table 2

Patients with neurological manifestations and positive sars-cov-2 rt-pcr in csf, clinical and paraclinical findings.

AuthorCSF WBC/mm3CSF protein (mg/dl)CSF glucose (mg/dl)RT-PCR for SARS-CoV-2 in nasopharyngeal swabClinical manifestationBrain/Spinal cord MRI findings
Moriguchi et al. (Moriguchi et al., 2020)12 – 83% mononuclearNot availableNot availableNegativeMeningoencephalitisFLAIR hyperintensity within the right mesial temporal lobe and hippocampus with slight hippocampal atrophy. Hyperintensity along the wall of right lateral ventricle on DWI. No pathological contrast enhancement.
Virhammar et al. (Virhammar et al., 2020)No cellsIncreasedNot availablePositiveAcute necrotizing encephalopathySymmetrical T2/FLAIR hyperintensities in subinsular region, medial temporal lobes and thalami, with restricted diffusion, contrast enhancement and small foci of decreased signal on SWI. FLAIR increased signal in the brain stem.
Khodamoradi et al. (Khodamoradi et al., 2020)1st) 90 – 100% mononuclear2nd) 23 – 56.5% mononuclear0.26854540.3NegativeMeningitisNormal
Domingues et al. (Barros Domingues et al., 2020)13268NegativeSensory symptomsHyperintensity lesion on T2/STIR sequence at C6 level.
Helms et al. (Helms et al., 2020)Not availableNot availableNot availablePositiveDeliriumNot available
Fadakar et al. (Fadakar et al., 2020)Mild pleocytosisIncreasedNormalPositiveCerebellitisBilateral cerebellar hemispheres and vermis hyperintensities on FLAIR, with T1 post contrast cerebellar cortical-meningeal enhancement.
Huang et al. (Huang et al., 2020)70 – 100% mononuclear100120PositiveMeningoencephalitisNot available.Normal brain CT.
Westhaff et al. (Westhoff et al., 2020)111093PositiveMeningoencephalitisWhite matter hyperintensities on T2 sequence, T1 post contrast linear meningeal enhancement and subtle area of diffusion restriction in the right frontal lobe.
Mardani et al. (Mardani et al., 2020)1920 - 90% polymorphonuclear94.8 ​g/l10PositiveEncephalitisNot available.Brain CT with mild cortical atrophy.
Cebrián et al. (Cebrián et al., 2020)13082PositiveHeadache, impaired consciousness, acute ischemic strokeCorticosubcortical focal area of restricted diffusion in right parietal lobe.
Novi et al. (Novi et al., 2020)22 – predominantly mononuclear45.2Not availableNegativeAcute disseminated encephalomyelitisMultiple T1 post contrast enhancing lesions in the brain, associated with an enhancing single spinal cord lesion at the Th8 level and bilateral optic nerve enhancement.
Luis et al.1st) 02nd) 380 – 90% mononuclear1st)2472nd)98.31st)372nd)57NegativeMeningoencephalitis and myelitisFLAIR hyperintensities involving the cerebellum, thalamus and basal ganglia. Focal area of restricted diffusion in the splenium of the corpus callosum. STIR signal hyperintensity extending from C2 to Th3 level and from Th5 to Th10, with patchy and eccentric contrast enhancement. T1 post contrast cervical and lumbar pial enhancement associated to conus medullaris enhancement.
Luis et al.095.943PositiveEncephalitisNormal

FLAIR: Fluid-attenuated inversion-recovery; DWI: Diffusion-weighted imaging; SWI: Susceptibility-weighted images; STIR: Short Tau Inversion Recovery.

Patients with neurological manifestations and positive sars-cov-2 rt-pcr in csf, clinical and paraclinical findings. FLAIR: Fluid-attenuated inversion-recovery; DWI: Diffusion-weighted imaging; SWI: Susceptibility-weighted images; STIR: Short Tau Inversion Recovery. As far as neuroimaging is concerned, most commonly reported findings represent cases of cerebrovascular disease. Based on a recent systematic review, the possible SARS-CoV2-2 brain MRI patterns are large vessel occlusion infarction, usually with hemorrhagic transformation; lobar and cortical intracerebral hemorrhage; multiple callosal and juxtacortical white matter cerebral microbleeds and hemorrhagic necrotizing encephalopathy (Ladopoulos et al., 2021). Nevertheless, as these features are also seen in critical ill patients, the direct association with SARS-CoV-2 infection is still to be determined. No typical feature of SARS-CoV-2 associated demyelination, leukoencephalopathy and myelitis was identified. Other imaging findings are cerebral venous sinus thrombosis, posterior reversible encephalopathy syndrome, cytotoxic lesion in the corpus callosum, basal ganglia abnormalities, leptomeningeal, cranial and spinal nerve enhancement (Ladopoulos et al., 2021), (Chougar et al., 2020), (Klironomos et al., 2020), (Kremer et al., 2020). Up to now, seven cases of SARS-CoV-2 associated myelitis have been published, only one with viral RNA presence in CSF (Munz et al., 2020), (AlKetbi et al., 2020), (Sotoca and Rodríguez-Álvarez, 2020), (Valiuddin et al., 2020), (Zanin et al., 2020), (Sarma and Bilello, 2020), (Zhao et al., 2020). Clinical and imaging findings are described in Table 3.
Table 3

Clinical and imaging features of sars-cov-2 associated myelitis.

AuthorClinical manifestationsSpinal cord MRI findingsBrain MRI findingsRT-PCR SAR-CoV-2 in CSF
Munz et al. (Munz et al., 2020)Spastic paraparesis, hypoesthesia below the Th9 level, bladder dysfunction.T2 signal hyperintensity at Th3-5 and Th9-10 level.NormalNegative
AlKetbi et al. (AlKetbi et al., 2020)Distal paresis of upper limbs and paraplegia, truncal weakness, urinary retention.Hyperintense signal involving predominantly the grey matter of the cervical, dorsal and lumbar regions, with restricted diffusion and no contrast enhancement. Mild enlargement and swelling of the cervical cord.Not availableNot available
Sotoca et al. (Sotoca and Rodríguez-Álvarez, 2020)Cervical pain, imbalance, subtle weakness of left hand, right facial and left hand hypoesthesia.T2 signal hyperintensity extending from the medulla oblongata to Th6, with swelling and diffuse patchy enhancing lesions. Area of central necrosis at Th1 level with peripheral enhancement (Acute necrotizing myelitis)NormalNegative
Valiuddin et al. (Valiuddin et al., 2020)Tetraparesis, paresthesias in hands, abdomen and lower limbs, constipation.Patchy T2 signal hyperintensity throughout the entire length of the cervical cord with mild swelling, without contrast enhancement.Not availableNegative
Zanin et al. (Zanin et al., 2020)Impaired state of consciousness.Focal T2 signal hyperintensity in bulb-medullary junction, C2 level and from C3 to Th6, without contrast enhancement.T2 hyperintensity signal of the periventricular white matter, without contrast enhancement.Negative
Sarma et al. (Sarma and Bilello, 2020)Mild weakness among with paresthesias and decreased proprioception in upper limbs, hypoesthesia below the Th5 level, Lhermitte´s sign, low back pain, wide-based gait, urinary retention.Signal changes throughout the spinal cord to the conus medullaris.Not available.Not available
Zhao et al.Paresis of upper limbs and paraplegia, hypoesthesia in lower limbs, sensory level at Th10, urinary and bowel incontinence.Not availableNot availableNot available
Novi et al. (Novi et al., 2020)Bilateral vision impairment, headache, irritability, right abdominal sensory level, hypoesthesia on the right leg, ageusia and anosmia.T2 signal hyperintensity at Th8 level, involving less than 2 metameric levels, with eccentric areas of contrast enhancement.Multiple T1 post contrast enhancing lesions and bilateral optic nerve enhancement.Positive
Luis et al.Headache, fever, vomits, nuchal rigidity, impaired consciousness, seizures, ataxia, urinary retention.STIR signal hyperintensity extending from C2 to Th3 level and from Th5 to Th10 (longitudinally extensive myelitis), with patchy and eccentric contrast enhancement. T1 post contrast cervical and lumbar pial enhancement associated to conus medullaris enhancement.FLAIR hyperintensities involving the cerebellum, thalamus and basal ganglia. Focal area of restricted diffusion in the splenium of the corpus callosum.Positive

STIR: Short Tau Inversion Recovery; FLAIR: Fluid-attenuated inversion-recovery.

Clinical and imaging features of sars-cov-2 associated myelitis. STIR: Short Tau Inversion Recovery; FLAIR: Fluid-attenuated inversion-recovery.

Conclusions

SARS-CoV-2 can affect the nervous system in any stage of infection, and neurological complications can even represent the only manifestation of the disease. Nevertheless, they are currently underdiagnosed and viral RNA detection in CSF is infrequent. In patients with neurological symptoms, SARS-CoV-2 infection should be considered in order to avoid delayed diagnosis and prevent transmission.

Ethical approval

The ethical review board approved this manuscript.

Consent

CASE 1: Consent-to-disclose was signed by a patient´s family member. CASE 2: Consent-to-disclose was signed by the patient.

Declaration of competing interest

The authors declare that there is no conflict of interest.
  33 in total

1.  Allograft infiltration and meningoencephalitis by SARS-CoV-2 in a pancreas-kidney transplant recipient.

Authors:  Timm H Westhoff; Felix S Seibert; Frederic Bauer; Ulrik Stervbo; Moritz Anft; Adrian A N Doevelaar; Benjamin J Rohn; Guido Winnekendonk; Ulf Dittmer; Peter Schenker; Eva Vonbrunn; Kerstin Amann; Richard Viebahn; Nina Babel
Journal:  Am J Transplant       Date:  2020-08-30       Impact factor: 8.086

2.  Headache and impaired consciousness level associated with SARS-CoV-2 in CSF: A case report.

Authors:  José Cebrián; Alicia Gonzalez-Martinez; María J García-Blanco; Diego Celdrán-Vivancos; Eduardo López Palacios; Gemma Reig-Roselló; Laura Casado-Fernández; José Vivancos; Ana Beatriz Gago-Veiga
Journal:  Neurology       Date:  2020-07-08       Impact factor: 9.910

3.  Acute transverse myelitis associated with SARS-CoV-2: A Case-Report.

Authors:  Hisham Valiuddin; Brandon Skwirsk; Patricia Paz-Arabo
Journal:  Brain Behav Immun Health       Date:  2020-06-06

4.  COVID-19-associated acute necrotizing myelitis.

Authors:  Javier Sotoca; Yensa Rodríguez-Álvarez
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-06-10

5.  Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7).

Authors: 
Journal:  Chin Med J (Engl)       Date:  2020-05-05       Impact factor: 2.628

6.  SARS-CoV-2 can induce brain and spine demyelinating lesions.

Authors:  Luca Zanin; Giorgio Saraceno; Pier Paolo Panciani; Giulia Renisi; Liana Signorini; Karol Migliorati; Marco Maria Fontanella
Journal:  Acta Neurochir (Wien)       Date:  2020-05-04       Impact factor: 2.216

7.  Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid.

Authors:  Johan Virhammar; Eva Kumlien; David Fällmar; Robert Frithiof; Sven Jackmann; Mattias K Sköld; Mohamed Kadir; Jens Frick; Jonas Lindeberg; Henrik Olivero-Reinius; Mats Ryttlefors; Janet L Cunningham; Johan Wikström; Anna Grabowska; Kåre Bondeson; Jonas Bergquist; Henrik Zetterberg; Elham Rostami
Journal:  Neurology       Date:  2020-06-25       Impact factor: 9.910

8.  High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms.

Authors:  Christiana Franke; Caroline Ferse; Jakob Kreye; S Momsen Reincke; Elisa Sanchez-Sendin; Andrea Rocco; Mirja Steinbrenner; Stefan Angermair; Sascha Treskatsch; Daniel Zickler; Kai-Uwe Eckardt; Rick Dersch; Jonas Hosp; Heinrich J Audebert; Matthias Endres; J Christoph Ploner; Harald Prüß
Journal:  Brain Behav Immun       Date:  2020-12-24       Impact factor: 7.217

Review 9.  Nervous system involvement after infection with COVID-19 and other coronaviruses.

Authors:  Yeshun Wu; Xiaolin Xu; Zijun Chen; Jiahao Duan; Kenji Hashimoto; Ling Yang; Cunming Liu; Chun Yang
Journal:  Brain Behav Immun       Date:  2020-03-30       Impact factor: 7.217

10.  Neurological manifestations of COVID-19: a systematic review and meta-analysis of proportions.

Authors:  T T Favas; Priya Dev; Rameshwar Nath Chaurasia; Kamlesh Chakravarty; Rahul Mishra; Deepika Joshi; Vijay Nath Mishra; Anand Kumar; Varun Kumar Singh; Manoj Pandey; Abhishek Pathak
Journal:  Neurol Sci       Date:  2020-10-21       Impact factor: 3.830

View more
  5 in total

1.  Potential role of astrocyte angiotensin converting enzyme 2 in the neural transmission of COVID-19 and a neuroinflammatory state induced by smoking and vaping.

Authors:  Yong Zhang; Sabrina Rahman Archie; Yashwardhan Ghanwatkar; Sejal Sharma; Saeideh Nozohouri; Elizabeth Burks; Alexander Mdzinarishvili; Zijuan Liu; Thomas J Abbruscato
Journal:  Fluids Barriers CNS       Date:  2022-06-07

Review 2.  Opioid-Use, COVID-19 Infection, and Their Neurological Implications.

Authors:  Richa Jalodia; Danielle Antoine; Regina Gonzalez Braniff; Rajib Kumar Dutta; Sundaram Ramakrishnan; Sabita Roy
Journal:  Front Neurol       Date:  2022-05-23       Impact factor: 4.086

3.  Comments on "CSF-Confirmed SARS-CoV-2 Acute Encephalitis": SARS-CoV-2-Associated Encephalitis Is Autoimmune Rather Than Infectious.

Authors:  Josef Finsterer; Fulvio Alexandre Scorza; Ana Claudia Fiorini
Journal:  J Clin Neurol       Date:  2022-01       Impact factor: 3.077

4.  SARS-CoV-2 infection of the central nervous system in a 14-month-old child: A case report of a complete autopsy.

Authors:  Ismael Gomes; Karina Karmirian; Júlia T Oliveira; Carolina da S G Pedrosa; Mayara Abud Mendes; Fernando Colonna Rosman; Leila Chimelli; Stevens Rehen
Journal:  Lancet Reg Health Am       Date:  2021-08-28

Review 5.  Can SARS-CoV-2 Infection Lead to Neurodegeneration and Parkinson's Disease?

Authors:  Lea Krey; Meret Koroni Huber; Günter U Höglinger; Florian Wegner
Journal:  Brain Sci       Date:  2021-12-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.